PolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET
Company Participants
Dikla Czaczkes Akselbrad – CEO & Director
Jonny Missulawin – Chief Financial Officer
Ori Warshavsky – Chief Operating Officer—US
Conference Call Participants
Chase Richard Knickerbocker – Craig-Hallum Capital Group LLC, Research Division
Douglas Royal Buchanan – Citizens JMP Securities, LLC, Research Division
Yehuda Leibler – Unidentified Company
Operator
Greetings, and welcome to PolyPid’s Second Quarter 2025 Conference Call. [Operator Instructions] As a reminder, this call is recorded. And I would now like to introduce your host for today’s conference, Yehuda Leibler from ARX Capital Markets. Mr. Leibler, you may begin.
Yehuda Leibler
Thank you all for participating in PolyPid’s Second Quarter 2025 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid’s Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer, U.S. of PolyPid.
Earlier today, PolyPid released its financial results for the 3 months ended June 30, 2025. A copy of the press release is available in the Investors section on the company’s website available at www.polypid.com. I’d like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities law. For example, management is making forward- looking statements when it discusses D-PLEX100’s potential benefits, including its potential to address a significant unmet medical need and to substantially reduce the burden of surgical site infections, improve patient outcomes and generate meaningful health care cost savings, the expected regulatory submissions and their timing, the aim of GLP-1 program and its potential to address significant unmet medical needs in the treatment of metabolic diseases, the company’s expected cash runway and the potential partnership opportunities for D-PLEX100.
Forward-looking statements are subject to numerous risks and uncertainties, many
#PolyPid #PYPD #Earnings #Call #Transcript